Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 1
2007 2
2009 1
2010 5
2011 3
2012 2
2013 2
2014 1
2015 5
2016 6
2017 12
2018 12
2019 7
2020 5
2021 10
2022 10
2023 6
2024 9
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Chen HK, Su PJ, Wang YL, Chang KC, Su YL, Chang PH, Kuan FC, Hsieh CH, Kuo YC, Sheng TW, Chang CF, Yu SM, Huang WK, Lin YC, Tsan DL, Yu KJ, Lin PH, Chen HY, Chang YH, Pang ST, Chuang CK, Lai EC. Chen HK, et al. Among authors: chang yh. Int J Cancer. 2023 Mar 15;152(6):1191-1201. doi: 10.1002/ijc.34348. Epub 2022 Dec 9. Int J Cancer. 2023. PMID: 36346116
Erectile dysfunction and the risk of prostate cancer.
Lin WY, Chang YH, Lin CL, Kao CH, Wu HC. Lin WY, et al. Among authors: chang yh. Oncotarget. 2017 Apr 13;8(32):52690-52698. doi: 10.18632/oncotarget.17082. eCollection 2017 Aug 8. Oncotarget. 2017. PMID: 28881762 Free PMC article.
Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer.
Lee CL, Chang YH, Liu CY, Hsieh ML, Huang LK, Chu YC, Kan HC, Lin PH, Yu KJ, Chuang CK, Wu CT, Pang ST, Shao IH. Lee CL, et al. Among authors: chang yh. Investig Clin Urol. 2022 Sep;63(5):546-553. doi: 10.4111/icu.20210450. Investig Clin Urol. 2022. PMID: 36068000 Free PMC article.
96 results